Karnofsky Performance Status
"Karnofsky Performance Status" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A performance measure for rating the ability of a person to perform usual activities, evaluating a patient's progress after a therapeutic procedure, and determining a patient's suitability for therapy. It is used most commonly in the prognosis of cancer therapy, usually after chemotherapy and customarily administered before and after therapy. It was named for Dr. David A. Karnofsky, an American specialist in cancer chemotherapy.
| Descriptor ID |
D017567
|
| MeSH Number(s) |
E05.318.308.980.438.475.456.500.500 N05.715.360.300.800.438.375.364.500.500 N06.850.520.308.980.438.475.364.500.500
|
| Concept/Terms |
Karnofsky Performance Status- Karnofsky Performance Status
- Performance Status, Karnofsky
- Status, Karnofsky Performance
- Karnofsky Performance Status Scale
- Karnofsky Scale
- Scale, Karnofsky
- Karnofsky Index
- Index, Karnofsky
|
Below are MeSH descriptors whose meaning is more general than "Karnofsky Performance Status".
Below are MeSH descriptors whose meaning is more specific than "Karnofsky Performance Status".
This graph shows the total number of publications written about "Karnofsky Performance Status" by people in this website by year, and whether "Karnofsky Performance Status" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2017 | 0 | 10 | 10 |
| 2018 | 1 | 8 | 9 |
| 2019 | 0 | 1 | 1 |
| 2020 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Karnofsky Performance Status" by people in Profiles.
-
Three Proposals to Optimise the Eastern Cooperative Oncology Group and Karnofsky Scales in the Molecular and COVID-19 Era. Clin Oncol (R Coll Radiol). 2021 03; 33(3):e192.
-
Challenges and recommendations for cancer care in the COVID-19 pandemic. Cancer Biol Med. 2020 08 15; 17(3):515-518.
-
High mortality rate in cancer patients with symptoms of COVID-19 with or without detectable SARS-COV-2 on RT-PCR. Eur J Cancer. 2020 08; 135:251-259.
-
Utility of CT assessment in hematology patients with invasive aspergillosis: a post-hoc analysis of phase 3 data. BMC Infect Dis. 2019 May 28; 19(1):471.
-
Measure Me, Don't Judge Me: Patients as Objective Contributors to Performance Status Measurement. JCO Clin Cancer Inform. 2018 12; 2:1-4.
-
Critically ill healthcare workers with the middle east respiratory syndrome (MERS): A multicenter study. PLoS One. 2018; 13(11):e0206831.
-
The prognostic factors influencing overall survival in uterine cervical cancer with brain metastasis. Korean J Intern Med. 2019 Nov; 34(6):1324-1332.
-
Hypnosis-Aided Awake Surgery for the Management of Intrinsic Brain Tumors versus Standard Awake-Asleep-Awake Protocol: A Preliminary, Promising Experience. World Neurosurg. 2019 Jan; 121:e882-e891.
-
Phase II study of hypofractionated radiation therapy in elderly patients with newly diagnosed glioblastoma with poor prognosis. Tumori. 2019 Feb; 105(1):47-54.
-
Hypofractionated accelerated radiotherapy (HART) with concurrent and adjuvant temozolomide in newly diagnosed glioblastoma: a phase II randomized trial (HART-GBM trial). J Neurooncol. 2018 Oct; 140(1):75-82.